346 related articles for article (PubMed ID: 27340277)
1. Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase.
Kalinina J; Ahn J; Devi NS; Wang L; Li Y; Olson JJ; Glantz M; Smith T; Kim EL; Giese A; Jensen RL; Chen CC; Carter BS; Mao H; He M; Van Meir EG
Clin Cancer Res; 2016 Dec; 22(24):6256-6265. PubMed ID: 27340277
[TBL] [Abstract][Full Text] [Related]
2. IDH1 p.R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-mutant gliomas.
Fujita Y; Nunez-Rubiano L; Dono A; Bellman A; Shah M; Rodriguez JC; Putluri V; Kamal AHM; Putluri N; Riascos RF; Zhu JJ; Esquenazi Y; Ballester LY
J Neurooncol; 2022 Sep; 159(2):261-270. PubMed ID: 35816267
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.
Tietze A; Choi C; Mickey B; Maher EA; Parm Ulhøi B; Sangill R; Lassen-Ramshad Y; Lukacova S; Østergaard L; von Oettingen G
J Neurosurg; 2018 Feb; 128(2):391-398. PubMed ID: 28298040
[TBL] [Abstract][Full Text] [Related]
4. Intraoperative assessment of isocitrate dehydrogenase mutation status in human gliomas using desorption electrospray ionization-mass spectrometry.
Alfaro CM; Pirro V; Keating MF; Hattab EM; Cooks RG; Cohen-Gadol AA
J Neurosurg; 2019 Jan; 132(1):180-187. PubMed ID: 30611146
[TBL] [Abstract][Full Text] [Related]
5. Comparative Value of 2-Hydroxyglutarate-to-Lipid and Lactate Ratio versus 2-Hydroxyglutarate Concentration on MR Spectroscopic Images for Predicting Isocitrate Dehydrogenase Mutation Status in Gliomas.
Suh CH; Kim HS; Park JE; Jung SC; Choi CG; Woo DC; Lee HB; Kim SJ
Radiol Imaging Cancer; 2020 Jul; 2(4):e190083. PubMed ID: 33778723
[TBL] [Abstract][Full Text] [Related]
6. Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma.
Choi C; Raisanen JM; Ganji SK; Zhang S; McNeil SS; An Z; Madan A; Hatanpaa KJ; Vemireddy V; Sheppard CA; Oliver D; Hulsey KM; Tiwari V; Mashimo T; Battiste J; Barnett S; Madden CJ; Patel TR; Pan E; Malloy CR; Mickey BE; Bachoo RM; Maher EA
J Clin Oncol; 2016 Nov; 34(33):4030-4039. PubMed ID: 28248126
[TBL] [Abstract][Full Text] [Related]
7. Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients.
Jafari-Khouzani K; Loebel F; Bogner W; Rapalino O; Gonzalez GR; Gerstner E; Chi AS; Batchelor TT; Rosen BR; Unkelbach J; Shih HA; Cahill DP; Andronesi OC
Neuro Oncol; 2016 Nov; 18(11):1569-1578. PubMed ID: 27382115
[TBL] [Abstract][Full Text] [Related]
8. Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.
Andronesi OC; Loebel F; Bogner W; Marjańska M; Vander Heiden MG; Iafrate AJ; Dietrich J; Batchelor TT; Gerstner ER; Kaelin WG; Chi AS; Rosen BR; Cahill DP
Clin Cancer Res; 2016 Apr; 22(7):1632-41. PubMed ID: 26534967
[TBL] [Abstract][Full Text] [Related]
9. Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy.
Natsumeda M; Igarashi H; Nomura T; Ogura R; Tsukamoto Y; Kobayashi T; Aoki H; Okamoto K; Kakita A; Takahashi H; Nakada T; Fujii Y
Acta Neuropathol Commun; 2014 Nov; 2():158. PubMed ID: 25376594
[TBL] [Abstract][Full Text] [Related]
10. Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.
Delahousse J; Verlingue L; Broutin S; Legoupil C; Touat M; Doucet L; Ammari S; Lacroix L; Ducreux M; Scoazec JY; Malka D; Paci A; Hollebecque A
Eur J Cancer; 2018 Feb; 90():83-91. PubMed ID: 29274619
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma.
Lombardi G; Corona G; Bellu L; Della Puppa A; Pambuku A; Fiduccia P; Bertorelle R; Gardiman MP; D'Avella D; Toffoli G; Zagonel V
Oncologist; 2015 May; 20(5):562-7. PubMed ID: 25862748
[TBL] [Abstract][Full Text] [Related]
12. Tissue 2-Hydroxyglutarate and Preoperative Seizures in Patients With Diffuse Gliomas.
Ohno M; Hayashi Y; Aikawa H; Hayashi M; Miyakita Y; Takahashi M; Matsushita Y; Yoshida A; Satomi K; Ichimura K; Hamada A; Narita Y
Neurology; 2021 Nov; 97(21):e2114-e2123. PubMed ID: 34610989
[TBL] [Abstract][Full Text] [Related]
13. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas.
Choi C; Ganji SK; DeBerardinis RJ; Hatanpaa KJ; Rakheja D; Kovacs Z; Yang XL; Mashimo T; Raisanen JM; Marin-Valencia I; Pascual JM; Madden CJ; Mickey BE; Malloy CR; Bachoo RM; Maher EA
Nat Med; 2012 Jan; 18(4):624-9. PubMed ID: 22281806
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
Nagashima H; Tanaka K; Sasayama T; Irino Y; Sato N; Takeuchi Y; Kyotani K; Mukasa A; Mizukawa K; Sakata J; Yamamoto Y; Hosoda K; Itoh T; Sasaki R; Kohmura E
Neuro Oncol; 2016 Nov; 18(11):1559-1568. PubMed ID: 27154922
[TBL] [Abstract][Full Text] [Related]
15. Reliable diagnosis of IDH-mutant glioblastoma by 2-hydroxyglutarate detection: a study by 3-T magnetic resonance spectroscopy.
Natsumeda M; Motohashi K; Igarashi H; Nozawa T; Abe H; Tsukamoto Y; Ogura R; Okada M; Kobayashi T; Aoki H; Takahashi H; Kakita A; Okamoto K; Nakada T; Fujii Y
Neurosurg Rev; 2018 Apr; 41(2):641-647. PubMed ID: 28956184
[TBL] [Abstract][Full Text] [Related]
16. The diagnostic efficiency of integration of 2HG MRS and IVIM versus individual parameters for predicting IDH mutation status in gliomas in clinical scenarios: A retrospective study.
Yu M; Ge Y; Wang Z; Zhang Y; Hou X; Chen H; Chen X; Ji N; Li X; Shen H
J Neurooncol; 2024 Apr; 167(2):305-313. PubMed ID: 38424338
[TBL] [Abstract][Full Text] [Related]
17. Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry.
Longuespée R; Wefers AK; De Vita E; Miller AK; Reuss DE; Wick W; Herold-Mende C; Kriegsmann M; Schirmacher P; von Deimling A; Pusch S
Acta Neuropathol Commun; 2018 Mar; 6(1):21. PubMed ID: 29499756
[TBL] [Abstract][Full Text] [Related]
18. Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.
de la Fuente MI; Young RJ; Rubel J; Rosenblum M; Tisnado J; Briggs S; Arevalo-Perez J; Cross JR; Campos C; Straley K; Zhu D; Dong C; Thomas A; Omuro AA; Nolan CP; Pentsova E; Kaley TJ; Oh JH; Noeske R; Maher E; Choi C; Gutin PH; Holodny AI; Yen K; DeAngelis LM; Mellinghoff IK; Thakur SB
Neuro Oncol; 2016 Feb; 18(2):283-90. PubMed ID: 26691210
[TBL] [Abstract][Full Text] [Related]
19. Spectroscopic imaging of D-2-hydroxyglutarate and other metabolites in pre-surgical patients with IDH-mutant lower-grade gliomas.
Autry AW; Lafontaine M; Jalbert L; Phillips E; Phillips JJ; Villanueva-Meyer J; Berger MS; Chang SM; Li Y
J Neurooncol; 2022 Aug; 159(1):43-52. PubMed ID: 35672531
[TBL] [Abstract][Full Text] [Related]
20. Echo-planar spectroscopic imaging with dual-readout alternated gradients (DRAG-EPSI) at 7 T: Application for 2-hydroxyglutarate imaging in glioma patients.
An Z; Tiwari V; Ganji SK; Baxter J; Levy M; Pinho MC; Pan E; Maher EA; Patel TR; Mickey BE; Choi C
Magn Reson Med; 2018 Apr; 79(4):1851-1861. PubMed ID: 28833542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]